Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer's Disease. A 24-week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study.

Trial Profile

Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer's Disease. A 24-week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs S 38093 (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors IRIS; Servier
  • Most Recent Events

    • 21 Feb 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
    • 13 Dec 2012 New source identified and integrated (United Kingdom Clinical Research Network; 11864).
    • 08 Dec 2012 Additional lead trial centre identified as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top